Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageCencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR
Business segments
Q3 2026 · $81.46BThe company’s own SEC segment disclosure.
- US Healthcare Solutions$74.86B92%
- International Healthcare Solutions$6.60B8%
Cencora (COR) reported revenue of $84.8B in Q3 2026 (quarter ended Jun 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 4.3% and net income of $764M (0.9% of revenue). For the full year FY2025, revenue was $321.3B (+9.3% year on year) and net income $1.55B. Its largest segment in Q3 2026 was US Healthcare Solutions at $74.9B, 92% of the disclosed total, well ahead of International Healthcare Solutions at 8.1%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.